CODEX4SMEs – COMPANION DIAGNOSTICS EXPEDITED FOR SMES
The Codex4SMEs project aims to improve healthcare through increased adoption of personalised medicine. Its goal: to be able to provide “the right drug, at the right dose, at the right time, to the right patient”, enabling governments to achieve substantial healthcare savings. To achieve this goal, companion diagnostics (Cdx) are needed, but only a few therapies are currently accompanied by companion diagnostics in Europe.
This new market could benefit SMEs in North-Western Europe. The region lags behind the United States, which are much more advanced in the field, due to:
- The European Union regulation (the new directive on in vitro diagnostics only became effective in 2020)
- High development costs (> €5 million)
- Project length (> 5 years)
Codex4SMEs’ goal is to catch up, via a network of 11 partners from 7 countries (Germany, France, Netherlands, United Kingdom, Ireland, Luxembourg and Austria). The idea of the programme is to support around 200 SMEs at each phase of their development: incubation, acceleration and growth. Through support for knowledge transfer, access to samples and validation of biomarkers, 46 companies will manage to increase their TRL by at least one level, and at least 4 of them will achieve the full development of a new product. Finally, the Codex4SMEs project has a long-term ambition, with plans to collect more than 100 letters of intent from future partners.
PROJECT LEAD: BioRegio STERN Management GmbH
CALL FOR PROJECTS: INTERREG – North-West-Europe
EU FUNDING: €1.8M
TOTAL BUDGET: €3.13M
FUNDING YEAR: 2017
PARTNERS: BioRegio STERN Management GmbH – University of Leicester – BOM Holding BV – Innovation and Management Centre Limited T/A WestBIC – InnovationQuarter – Medicen Paris Region – Integrated BioBank of Luxembourg – CÚRAM, Research Centre for Medical Devices – Biobank Graz (Medical University of Graz)
COUNTRIES: United Kingdom, Netherlands, Ireland, France, Luxembourg, Austria